ClinicalTrials.gg
WithdrawnNCT02779192PANIHLUpdated Jun 3, 2026

A Phase 2b Study of SPI-1005 to Prevent Acute Noise Induced Hearing Loss

A Phase 2 interventional study of SPI-1005 200mg and SPI-1005 400mg in Noise Induced Hearing Loss, sponsored by Sound Pharmaceuticals, Incorporated. Withdrawn at 5 sites in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Sound Pharmaceuticals, Incorporated · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study did not start

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Hearing Loss, Noise-Induced with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Hearing Loss, Noise-Induced · United States.

Enrollment
21st of 22
0 · median 106
Started
2026
with 2 others
Phase 2
7 of 24
none open now
Registered
9th of 24
by date

Among the 24 studies in Hearing Loss, Noise-Induced with a site in United States, this one is the 21st largest by enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 2, and was the 9th registered.

Hearing Loss, Noise-Induced

46 studies on the registry are indexed under Hearing Loss, Noise-Induced; 10 are open to participants now.

Browse Hearing Loss, Noise-Induced studies →

Open to participants now

6 of the 24 studies in Hearing Loss, Noise-Induced with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Hearing Loss, Noise-Induced studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hearing Loss, Noise-Induced with a site in United States, or all of them as a file.
02

Study summary

SPI-1005 is a novel oral drug that contains a glutathione peroxidase mimetic (ebselen) that will be tested in subjects with a history of NIHL at risk for additional NIHL. The goal of this multi-center Phase 2b study is to determine whether SPI-1005 is effective in reducing an acute NIHL in this affected population. In this Phase 2b study subjects with prior NIHL will be enrolled and exposed to a calibrated sound challenge (CSC) that induces a slight acute NIHL.

Read the detailed description

Randomized, double-blind, placebo-controlled, safety and efficacy study of oral SPI-1005 in adults with Noise Induced Hearing Loss (NIHL). All recruited subjects will have their severity of NIHL determined before the start of SPI-1005 treatment using various hearing tests. Subjects will be enrolled and randomized to either placebo or SPI-1005. Subjects will be dosed with either placebo or SPI-1005 for 7 days, beginning 1 day before an acute NIHL. Subjects will have hearing tests performed before and immediately after a calibrated sound challenge (CSC). Follow-up hearing tests will be performed post-CSC.

03

Conditions studied

  • Noise Induced Hearing Loss

Keywords

  • Acute Noise Induced Hearing Loss
  • Prevent Acute Noise Induced Hearing Loss
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult male or female patients, 18-50 years of age
  • History of either recreational and/or occupational exposure to noise
  • Voluntarily consent to participate in the study
  • Females of should be using and committed to continue using one of the following acceptable methods: Sexual abstinence (inactivity) for 14 days prior to screening through study completion; or intra-uterine device in place for at least 3 months prior to study through study completion; or barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening through study completion; or stable hormonal contraceptive for at least 3 months prior to study through study completion; or surgical sterilization (vasectomy) of partner at least 6 months prior to study.
  • Females of non-childbearing potential should be surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral oophorectomy at least 2 months prior to study) or be at least 3 years since last menses.

Exclusion criteria

Exclusion Criteria:

  • Current use or within 60 days prior to study of excluded ototoxic medications
  • History of inner ear disease
  • History of middle ear or inner ear surgery
  • Current conductive hearing loss or middle ear effusion
  • Significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, or psychiatric disease
  • History of or idiosyncratic reaction to compounds related to ebselen
  • Current use or within 30 days prior to study of drugs or substances known to be strong inhibitors or inducers of cytochrome P450 enzymes
  • Participation in another drug or device study within 90 days prior to study enrollment
  • Female patients who are pregnant or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    SPI-1005 200 mg

    200 mg SPI-1005, capsule, bid, po, x7d

    Drug: SPI-1005 200mg

  • Active comparator
    SPI-1005 400 mg

    400 mg SPI-1005, capsule, bid, po, x7d

    Drug: SPI-1005 400mg

  • Placebo comparator
    Placebo

    0 mg SPI-1005, capsule, bid, po, x7d

    Drug: Placebo

Interventions

  • Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days

    Also known as: Low Dose

  • Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days

    Also known as: High Dose

  • DrugPlacebo

    Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days

    Also known as: Control

06

What researchers measure

Primary outcomes

  1. Reduction in the Incidence of a Significant Threshold Shift

    Post Controlled Sound Challenge pure tone audiometry will be compared with baseline

    Time frame: Within 1 day

Secondary outcomes

  1. Improvement in word recognition score

    Post Controlled Sound Challenge Words in Noise Test score will be compared with baseline

    Time frame: Within 1 day

Other outcomes

  1. Adverse events

    Adverse events due to study drug will be compared with placebo

    Time frame: Within 7 days

07

Study locations

5 sites
  • University of Miami
    Miami, Florida 33136, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66103, United States
  • MUSC
    Charleston, South Carolina 29425, United States
  • University of Texas Southwestern
    Dallas, Texas 75390, United States
  • Sound Pharmaceuticals, Inc.
    Seattle, Washington 98103, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2016
First posted
May 20, 2016
StartEst.
Jun 2026
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02779192
Lead sponsor
Sound Pharmaceuticals, Incorporated
Responsible party
Sponsor
First posted
May 20, 2016
Start date
Jun 2026 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Jun 3, 2026

Study contacts

Jonathan Kil, MD
study chair · SOUND PHARMACEUTICALS, INC.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ebselen

Start the discussion